Shopping Cart 0
Cart Subtotal
USD 0

Thyroid Cancer - Pipeline Review, H2 2018

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 2000

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 4000

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 6000
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Thyroid Cancer-Pipeline Review, H2 2018

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Thyroid Cancer-Pipeline Review, H2 2018, provides an overview of the Thyroid Cancer (Oncology) pipeline landscape.

Thyroid cancer is a cancer that starts in the thyroid gland. Symptoms include lump that can be felt through the skin on neck, difficulty swallowing, pain in neck and throat and swollen lymph nodes in neck. Predisposing factors include female, high levels of radiation and inherited genetic syndromes. Treatment includes surgery and thyroid hormone therapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Thyroid Cancer-Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Thyroid Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Thyroid Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Thyroid Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 2, 35, 24, 3, 17 and 1 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 4 and 4 molecules, respectively.

Thyroid Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Thyroid Cancer (Oncology).

- The pipeline guide reviews pipeline therapeutics for Thyroid Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Thyroid Cancer (Oncology) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Thyroid Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Thyroid Cancer (Oncology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Thyroid Cancer (Oncology).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Thyroid Cancer (Oncology) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 2

Introduction 5

Thyroid Cancer-Overview 6

Thyroid Cancer-Therapeutics Development 7

Thyroid Cancer-Therapeutics Assessment 20

Thyroid Cancer-Companies Involved in Therapeutics Development 32

Thyroid Cancer-Drug Profiles 57

Thyroid Cancer-Dormant Projects 576

Thyroid Cancer-Discontinued Products 579

Thyroid Cancer-Product Development Milestones 580

Appendix 594


List Of Figure

List of Figures

Number of Products under Development for Thyroid Cancer, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Number of Products by Top 10 Targets, H2 2018

Number of Products by Stage and Top 10 Targets, H2 2018

Number of Products by Top 10 Mechanism of Actions, H2 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Top 10 Molecule Types, H2 2018

Number of Products by Stage and Top 10 Molecule Types, H2 2018


List Of Table

List of Tables

Number of Products under Development for Thyroid Cancer, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Universities/Institutes, H2 2018

Number of Products by Stage and Target, H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Thyroid Cancer-Pipeline by AbbVie Inc, H2 2018

Thyroid Cancer-Pipeline by Advenchen Laboratories LLC, H2 2018

Thyroid Cancer-Pipeline by Bayer AG, H2 2018

Thyroid Cancer-Pipeline by BeiGene Ltd, H2 2018

Thyroid Cancer-Pipeline by Biovista Inc, H2 2018

Thyroid Cancer-Pipeline by Blueprint Medicines Corp, H2 2018

Thyroid Cancer-Pipeline by Boehringer Ingelheim GmbH, H2 2018

Thyroid Cancer-Pipeline by Bristol-Myers Squibb Co, H2 2018

Thyroid Cancer-Pipeline by Celgene Corp, H2 2018

Thyroid Cancer-Pipeline by Celldex Therapeutics Inc, H2 2018

Thyroid Cancer-Pipeline by Centrose LLC, H2 2018

Thyroid Cancer-Pipeline by CSPC Pharmaceutical Group Limited, H2 2018

Thyroid Cancer-Pipeline by Curis Inc, H2 2018

Thyroid Cancer-Pipeline by CytImmune Sciences Inc, H2 2018

Thyroid Cancer-Pipeline by Cytori Therapeutics Inc, H2 2018

Thyroid Cancer-Pipeline by Daiichi Sankyo Co Ltd, H2 2018

Thyroid Cancer-Pipeline by Debiopharm International SA, H2 2018

Thyroid Cancer-Pipeline by Ecrins Therapeutics SAS, H2 2018

Thyroid Cancer-Pipeline by Eisai Co Ltd, H2 2018

Thyroid Cancer-Pipeline by Ensol Biosciences Inc, H2 2018

Thyroid Cancer-Pipeline by Exelixis Inc, H2 2018

Thyroid Cancer-Pipeline by F. Hoffmann-La Roche Ltd, H2 2018

Thyroid Cancer-Pipeline by Genelux Corp, H2 2018

Thyroid Cancer-Pipeline by Genmab A/S, H2 2018

Thyroid Cancer-Pipeline by Gradalis Inc, H2 2018

Thyroid Cancer-Pipeline by Hutchison MediPharma Ltd, H2 2018

Thyroid Cancer-Pipeline by Immunomedics Inc, H2 2018

Thyroid Cancer-Pipeline by Johnson & Johnson, H2 2018

Thyroid Cancer-Pipeline by Konruns Pharmaceutical Co Ltd, H2 2018

Thyroid Cancer-Pipeline by Loxo Oncology Inc, H2 2018

Thyroid Cancer-Pipeline by MacroGenics Inc, H2 2018

Thyroid Cancer-Pipeline by MaxiVAX SA, H2 2018

Thyroid Cancer-Pipeline by MedImmune LLC, H2 2018

Thyroid Cancer-Pipeline by Merck & Co Inc, H2 2018

Thyroid Cancer-Pipeline by Mersana Therapeutics Inc, H2 2018

Thyroid Cancer-Pipeline by Millennium Pharmaceuticals Inc, H2 2018

Thyroid Cancer-Pipeline by Novartis AG, H2 2018

Thyroid Cancer-Pipeline by Ono Pharmaceutical Co Ltd, H2 2018

Thyroid Cancer-Pipeline by Pfizer Inc, H2 2018

Thyroid Cancer-Pipeline by Plexxikon Inc, H2 2018

Thyroid Cancer-Pipeline by Rodos BioTarget GmbH, H2 2018

Thyroid Cancer-Pipeline by Sino Biopharmaceutical Ltd, H2 2018

Thyroid Cancer-Pipeline by Synactix Pharmaceuticals Inc, H2 2018

Thyroid Cancer-Pipeline by Tarveda Therapeutics Inc, H2 2018

Thyroid Cancer-Pipeline by UbiVac LLC, H2 2018

Thyroid Cancer-Pipeline by Vaccinex Inc, H2 2018

Thyroid Cancer-Pipeline by Vascular Biogenics Ltd, H2 2018

Thyroid Cancer-Pipeline by Xspray Pharma AB, H2 2018

Thyroid Cancer-Dormant Projects, H2 2018

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

Thyroid Cancer Therapeutic Products under Development, Key Players in Thyroid Cancer Therapeutics, Thyroid Cancer Pipeline Overview, Thyroid Cancer Pipeline, Thyroid Cancer Pipeline Assessment


Companies

AbbVie Inc

Advenchen Laboratories LLC

Bayer AG

BeiGene Ltd

Biovista Inc

Blueprint Medicines Corp

Boehringer Ingelheim GmbH

Bristol-Myers Squibb Co

Celgene Corp

Celldex Therapeutics Inc

Centrose LLC

CSPC Pharmaceutical Group Limited

Curis Inc

CytImmune Sciences Inc

Cytori Therapeutics Inc

Daiichi Sankyo Co Ltd

Debiopharm International SA

Ecrins Therapeutics SAS

Eisai Co Ltd

Ensol Biosciences Inc

Exelixis Inc

F. Hoffmann-La Roche Ltd

Genelux Corp

Genmab A/S

Gradalis Inc

Hutchison MediPharma Ltd

Immunomedics Inc

Johnson & Johnson

Konruns Pharmaceutical Co Ltd

Loxo Oncology Inc

MacroGenics Inc

MaxiVAX SA

MedImmune LLC

Merck & Co Inc

Mersana Therapeutics Inc

Millennium Pharmaceuticals Inc

Novartis AG

Ono Pharmaceutical Co Ltd

Pfizer Inc

Plexxikon Inc

Rodos BioTarget GmbH

Sino Biopharmaceutical Ltd

Synactix Pharmaceuticals Inc

Tarveda Therapeutics Inc

UbiVac LLC

Vaccinex Inc

Vascular Biogenics Ltd

Xspray Pharma AB